Novartis Loses Court Appeal Over Medicare Drug Price Negotiation

The Trump administration notched a win Thursday in a challenge from Novartis AG to the Biden-era program that allows the US to negotiate drug prices for some of the most widely used and expensive medicines covered under Medicare.

The manufacturer failed to prove that the Medicare Drug Price Negotiation, a plan created under former President Joe Biden’s Inflation Reduction Act, violates certain amendments of the US Constitution, according to an opinion from the the US Court of Appeals for the Third Circuit.

The court, pointing to its recent decision in a similar suit from manufacturers, rejects Novartis’s claim that the ...